ArticleBMC nephrology2025
miR-7974 as a potential biomarker for lupus nephritis and its involvement in disease progression.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLupus nephritis (LN) is a prevalent and severe complication associated with systemic lupus erythematosus (SLE), posing a substantial risk to renal function and adversely affecting the quality of life of affected individuals. miRNAs play a crucial regulatory role in adaptive immune responses. However, the involvement of specific miRNAs in LN is rarely reported. This research aims to examine the clinical value of miR-7974, as well as the expression changes and interaction mechanisms of the miR-7974/DDAH1 axis in LN, and its impact on the pathogenesis of LN.
methodsThe expression levels of miR-7974 and DDAH1 were measured using real-time fluorescence quantification. CCK-8 was utilized to assess cell proliferation ability. ELISA was employed to quantify the levels of inflammatory factors. The binding of miR-7974 to DDAH1 was verified using a dual luciferase reporter gene assay.
resultsmiR-7974 is highly expressed in blood samples from patients with LN and LPS-induced HRMCs, whereas DDAH1 is expressed at low levels. The ROC curve suggests that miR-7974 possesses diagnostic value. The knockdown of miR-7974 and the overexpression of DDAH1 both inhibit cell proliferation and reduce levels of inflammatory cytokines. Additionally, miR-7974 negatively regulates DDAH1.
conclusionsmiR-7974 plays a role in the progression of LN by negatively regulating DDAH1. The miR-7974/DDAH1 axis may serve as a non-invasive biomarker and a potential therapeutic target for the diagnosis of LN.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.